Vyxeos Liposomal UK RWE: CREST-UK

Back to resources

Following the release of the CREST-UK retrospective chart study results, we interviewed Dr Priyanka Mehta, lead investigator of the RWE study. Watch as she gives her thoughts on the rationale behind the study, and the clinical impact it can have on UK adults with AML-MRC and t-AML.

For an in-depth look at the CREST UK data, explore our infographic to discover the efficacy and safety profile of Vyxeos Liposomal in the UK cohort. 

Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Learning material Real-world Data Safety Vyxeos Liposomal Data

ABBREVIATIONS

AML-MRC, acute myeloid leukaemia with myelodysplastic-related changes; RWE, real-world evidence; t-AML, therapy-related acute myeloid leukaemia

ADVERSE EVENTS REPORTING

Adverse events should be reported. For the UK, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

For the Republic of Ireland, reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue

Adverse events should also be reported to Jazz Pharmaceuticals by phone: +44 8081890387 (UK toll-free) or +353 1 968 1631 (Republic of Ireland).

UK-VYX-2200183 | December 2022